

Jacqueline A Shaw

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9205428/publications.pdf>

Version: 2024-02-01

101
papers

10,286
citations

76326

40
h-index

39675

94
g-index

106
all docs

106
docs citations

106
times ranked

16702
citing authors

#	ARTICLE	IF	CITATIONS
1	Tracking the Evolution of Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 2109-2121.	27.0	1,786
2	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. <i>Nature</i> , 2017, 545, 446-451.	27.8	1,287
3	Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. <i>Cell</i> , 2017, 171, 1259-1271.e11.	28.9	968
4	Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. <i>Cancer Cell</i> , 2018, 33, 649-663.e4.	16.8	448
5	Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. <i>Nucleic Acids Research</i> , 2012, 40, e82-e82.	14.5	356
6	Mapping of mutation causing Friedreich's ataxia to human chromosome 9. <i>Nature</i> , 1988, 334, 248-250.	27.8	343
7	Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. <i>Oncogene</i> , 2001, 20, 1509-1518.	5.9	341
8	Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. <i>Immunity</i> , 2017, 46, 577-586.	14.3	323
9	Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. <i>Clinical Cancer Research</i> , 2019, 25, 4255-4263.	7.0	281
10	A framework for the development of effective anti-metastatic agents. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 185-204.	27.6	223
11	Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine down-regulation of MMP expression in fibroblasts and tumour cells. <i>Journal of Pathology</i> , 2003, 201, 562-572.	4.5	195
12	Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts. <i>Clinical Cancer Research</i> , 2017, 23, 88-96.	7.0	186
13	Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study. <i>PLoS Biology</i> , 2014, 12, e1001906.	5.6	185
14	Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. <i>Genome Research</i> , 2012, 22, 220-231.	5.5	165
15	Influence of Plasma Processing on Recovery and Analysis of Circulating Nucleic Acids. <i>PLoS ONE</i> , 2013, 8, e77963.	2.5	159
16	Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptorâ€“Positive Metastatic Breast Cancer. <i>Clinical Chemistry</i> , 2015, 61, 974-982.	3.2	155
17	Glomerular expression of nephrin is decreased in acquired human nephrotic syndrome. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 1234-1237.	0.7	115
18	Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. <i>Breast Cancer Research</i> , 2009, 11, R24.	5.0	101

#	ARTICLE	IF	CITATIONS
19	The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review. <i>BMC Cancer</i> , 2017, 17, 697.	2.6	94
20	Factors that influence quality and yield of circulating-free DNA: A systematic review of the methodology literature. <i>Heliyon</i> , 2018, 4, e00699.	3.2	92
21	Isolation and Extraction of Circulating Tumor DNA from Patients with Small Cell Lung Cancer. <i>Annals of the New York Academy of Sciences</i> , 2008, 1137, 98-107.	3.8	90
22	Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas. <i>Journal of Pathology</i> , 2002, 198, 450-457.	4.5	89
23	Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 149.	5.0	89
24	Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer. <i>Clinical Chemistry</i> , 2017, 63, 532-541.	3.2	81
25	NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 581-590.	2.5	76
26	Detection of HER2 amplification in circulating free DNA in patients with breast cancer. <i>British Journal of Cancer</i> , 2011, 104, 1342-1348.	6.4	74
27	Cell-free DNA analysis in current cancer clinical trials: a review. <i>British Journal of Cancer</i> , 2022, 126, 391-400.	6.4	74
28	Reproducibility in the Quantification of mRNA Levels by RT-PCR-ELISA and RT Competitive-PCR-ELISA. <i>BioTechniques</i> , 1998, 24, 652-658.	1.8	69
29	Differential effects of cyclosporin and tacrolimus on the expression of fibrosis-associated genes in isolated glomeruli from renal transplants. <i>British Journal of Surgery</i> , 2002, 87, 1569-1575.	0.3	66
30	The Importance of Careful Blood Processing in Isolation of Cell-Free DNA. <i>Annals of the New York Academy of Sciences</i> , 2006, 1075, 313-317.	3.8	66
31	Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. <i>Nature Communications</i> , 2021, 12, 1751.	12.8	66
32	Microsatellite instability in early sporadic breast cancer. <i>British Journal of Cancer</i> , 1996, 73, 1393-1397.	6.4	65
33	Loss of heterozygosity at chromosome 6q in preinvasive and early invasive breast carcinomas. <i>British Journal of Cancer</i> , 1997, 75, 1324-1329.	6.4	65
34	Ectopic Expression of P-Cadherin Correlates with Promoter Hypomethylation Early in Colorectal Carcinogenesis and Enhanced Intestinal Crypt Fission <i>in vivo</i> . <i>Cancer Research</i> , 2008, 68, 7760-7768.	0.9	64
35	Microsatellite alterations plasma DNA of primary breast cancer patients. <i>Clinical Cancer Research</i> , 2000, 6, 1119-24.	7.0	64
36	Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor gene correlates with poor differentiation in early breast carcinomas. <i>British Journal of Cancer</i> , 1997, 76, 1558-1561.	6.4	63

#	ARTICLE	IF	CITATIONS
37	Matrix Metalloproteinase Single-Nucleotide Polymorphisms and Haplotypes Predict Breast Cancer Progression. <i>Clinical Cancer Research</i> , 2007, 13, 6673-6680.	7.0	55
38	Molecular pathology of breast cancer and its application to clinical management. <i>Cancer and Metastasis Reviews</i> , 1997, 16, 5-27.	5.9	53
39	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. <i>Cell Reports</i> , 2020, 31, 107550.	6.4	51
40	The pioneer factor PBX1 is a novel driver of metastatic progression in ER \pm -positive breast cancer. <i>Oncotarget</i> , 2015, 6, 21878-21891.	1.8	45
41	Vitamin C supplementation in normal subjects reduces constitutive ICAM-1 expression. <i>Biochemical and Biophysical Research Communications</i> , 2003, 308, 339-345.	2.1	44
42	Intrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion. <i>Breast Cancer Research</i> , 2007, 9, R67.	5.0	42
43	Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features. <i>Journal of Clinical Pathology</i> , 2001, 54, 300-306.	1.9	41
44	LMTK3 is implicated in endocrine resistance via multiple signaling pathways. <i>Oncogene</i> , 2013, 32, 3371-3380.	5.9	40
45	A local human V β 1 T cell population is associated with survival in nonsmall-cell lung cancer. <i>Nature Cancer</i> , 2022, 3, 696-709.	13.2	39
46	Sporadic breast cancer in young women: Prevalence of loss of heterozygosity at p53, BRCA1 and BRCA2. <i>International Journal of Cancer</i> , 2002, 98, 205-209.	5.1	38
47	Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 87221-87233.	1.8	38
48	Expression of tenascin-C and its isoforms in the breast. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 595-606.	5.9	37
49	Using DNA sequencing data to quantify T cell fraction and therapy response. <i>Nature</i> , 2021, 597, 555-560.	27.8	36
50	â€œAcadianâ€ and â€œclassicalâ€ forms of Friedreich ataxia are most probably caused by mutations at the same locus. <i>American Journal of Medical Genetics Part A</i> , 1989, 33, 266-268.	2.4	35
51	A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation. <i>Scientific Reports</i> , 2020, 10, 4553.	3.3	35
52	Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity. <i>Cell Death and Disease</i> , 2018, 9, 894.	6.3	34
53	Effects of oral vitamin C on monocyte: endothelial cell adhesion in healthy subjects. <i>Biochemical and Biophysical Research Communications</i> , 2002, 294, 1161-1168.	2.1	33
54	Circulating tumor cells and plasma DNA analysis in patients with indeterminate early or metastatic breast cancer. <i>Biomarkers in Medicine</i> , 2011, 5, 87-91.	1.4	31

#	ARTICLE	IF	CITATIONS
55	Microsatellite instability in ductal carcinoma in situ of the breast. , 1998, 185, 18-24.		29
56	Circulating tumour-derived DNA in metastatic soft tissue sarcoma. <i>Oncotarget</i> , 2018, 9, 10549-10560.	1.8	29
57	Association of invasion-promoting tenascin-C additional domains with breast cancers in young women. <i>Breast Cancer Research</i> , 2010, 12, R57.	5.0	28
58	Identification of CpG islands in a physical map encompassing the Friedreich's ataxia locus. <i>Genomics</i> , 1991, 9, 90-95.	2.9	27
59	Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma. <i>British Journal of Cancer</i> , 2020, 123, 1271-1279.	6.4	27
60	AMPLIFICATION OF SPECIFIC mRNA FROM A SINGLE HUMAN RENAL GLOMERULUS, WITH AN APPROACH TO THE SEPARATION OF EPITHELIAL CELL mRNA. , 1996, 180, 188-193.		23
61	The liquid biopsy: towards standardisation in preparation for prime time. <i>Lancet Oncology</i> , The, 2019, 20, 758-760.	10.7	23
62	Circulating free DNA in the management of breast cancer. <i>Annals of Translational Medicine</i> , 2014, 2, 3.	1.7	23
63	Opportunities and challenges of circulating biomarkers in neuroblastoma. <i>Open Biology</i> , 2019, 9, 190056.	3.6	22
64	Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 295-309.	2.5	21
65	The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 751-755.	3.1	21
66	Telomere instability detected in sporadic colon cancers, some showing mutations in a mismatch repair gene. <i>Oncogene</i> , 2004, 23, 3434-3443.	5.9	20
67	Hide and seek: tell-tale signs of breast cancer lurking in the blood. <i>Cancer and Metastasis Reviews</i> , 2013, 32, 289-302.	5.9	18
68	Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF- κ B. <i>Oncogene</i> , 2021, 40, 1077-1090.	5.9	18
69	Evidence that superficial basal cell carcinoma is monoclonal from analysis of the <i>Ptch1</i> gene locus. <i>British Journal of Dermatology</i> , 2002, 147, 931-935.	1.5	17
70	KSR1 regulates BRCA1 degradation and inhibits breast cancer growth. <i>Oncogene</i> , 2015, 34, 2103-2114.	5.9	17
71	The presence of disseminated tumour cells in the bone marrow is inversely related to circulating free DNA in plasma in breast cancer dormancy. <i>British Journal of Cancer</i> , 2012, 106, 375-382.	6.4	16
72	Early detection of pre-malignant lesions in a KRASG12D-driven mouse lung cancer model by monitoring circulating free DNA. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	2.4	16

#	ARTICLE	IF	CITATIONS
73	Whole Genome Sequence Analysis Suggests Intratumoral Heterogeneity in Dissemination of Breast Cancer to Lymph Nodes. PLoS ONE, 2014, 9, e115346.	2.5	15
74	SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer. Clinical Cancer Research, 2016, 22, 479-491.	7.0	14
75	Expression of oestrogen receptor alpha variants in non-malignant breast and early invasive breast carcinomas. Journal of Pathology, 2000, 192, 159-165.	4.5	13
76	An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study). Annals of Oncology, 2013, 24, 924-930.	1.2	13
77	Diagnostic accuracy of circulating-free DNA for the determination of MYCN amplification status in advanced-stage neuroblastoma: a systematic review and meta-analysis. British Journal of Cancer, 2020, 122, 1077-1084.	6.4	13
78	Circulating cell-free DNA levels are associated with adverse outcomes in heart failure: testing liquid biopsy in heart failure. European Journal of Preventive Cardiology, 2020, 28, e28-e31.	1.8	12
79	Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease. JCO Precision Oncology, 2021, 5, 1768-1776.	3.0	12
80	The genetics of gastroesophageal adenocarcinoma and the use of circulating cell free DNA for disease detection and monitoring. Expert Review of Molecular Diagnostics, 2017, 17, 459-470.	3.1	11
81	Inactive matrix metalloproteinase 2 is a normal constituent of human glomerular basement membrane. An immuno-electron microscopic study. Journal of Pathology, 2000, 191, 61-66.	4.5	9
82	Detection of Breast Cancer ESR1 p.E380Q Mutation on an ISFET Lab-on-Chip Platform. , 2020, , .		9
83	The Circulating Nucleic Acid Characteristics of Non-Metastatic Soft Tissue Sarcoma Patients. International Journal of Molecular Sciences, 2020, 21, 4483.	4.1	8
84	Exclusion of the Friedreich ataxia gene from chromosome 19. Human Genetics, 1987, 76, 186-190.	3.8	6
85	Î±-Tocopherol supplementation does not affect monocyte endothelial adhesion or C-reactive protein levels but reduces soluble vascular adhesion molecule-1 in the plasma of healthy subjects. Redox Report, 2006, 11, 214-222.	4.5	6
86	Longitudinal whole-exome sequencing of cell-free DNA for tracking the co-evolutionary tumor and immune evasion dynamics: longitudinal data from a single patient. Annals of Oncology, 2021, 32, 681-684.	1.2	6
87	Numerical chromosomal aberrations in Hodgkin's disease detected by in situ hybridisation on routine paraffin sections.. Journal of Clinical Pathology, 1997, 50, 553-558.	2.0	5
88	Peptide nucleic acid clamping to improve the sensitivity of Ion Torrent-based detection of an oncogenic mutation in <i>KRAS</i> . Matters, 0, , .	1.0	5
89	Prevalence of ctDNA in early screen-detected breast cancers using highly sensitive and specific dual molecular barcoded personalised mutation assays. Annals of Oncology, 2021, 32, 1057-1060.	1.2	4
90	Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay. NAR Cancer, 2022, 4, .	3.1	4

#	ARTICLE	IF	CITATIONS
91	The prognostic role of circulating tumor cells in heavily pretreated individuals with a low life expectancy. <i>Future Oncology</i> , 2014, 10, 2555-2560.	2.4	2
92	A response to the Chief Medical Officer's report on Genomic Medicine: a catalyst for transformation. <i>Personalized Medicine</i> , 2018, 15, 5-8.	1.5	2
93	AMPLIFICATION OF SPECIFIC mRNA FROM A SINGLE HUMAN RENAL GLOMERULUS, WITH AN APPROACH TO THE SEPARATION OF EPITHELIAL CELL mRNA. <i>Journal of Pathology</i> , 1996, 180, 188-193.	4.5	2
94	A preliminary study to compare cfDNA levels in lung cancer cases and high risk controls to evaluate the role of cfDNA levels in early lung cancer detection. <i>European Journal of Surgical Oncology</i> , 2016, 42, S243-S244.	1.0	1
95	Telomere maintenance in soft tissue sarcomas. <i>Journal of Clinical Pathology</i> , 2017, 70, 371-377.	2.0	1
96	Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 465-476.	2.5	1
97	Genomic instability in pre-neoplastic colonic lesions. <i>Oncogene</i> , 2013, 32, 5331-5332.	5.9	0
98	Use of the liquid biopsy for monitoring patients with cancer. <i>Pathology</i> , 2018, 50, S32.	0.6	0
99	Liquid biopsies: An introduction to circulating tumour cells and ctDNA. <i>Pathology</i> , 2018, 50, S30.	0.6	0
100	Integrating next generation sequencing into the clinic. <i>Pathology</i> , 2018, 50, S30-S31.	0.6	0
101	Determination of Breast Cancer Dormancy: Analysis of Circulating Free DNA Using SNP 6.0 Arrays. , 2013, , 35-50.		0